|
Liver neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Overexpression of SUMO-1 in hepatocellular carcinoma: a latent target for diagnosis and therapy of hepatoma.
|
20502916 |
2011 |
|
Lymphoma
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Epstein-Barr Virus Latent Membrane Protein-1 Induces the Expression of SUMO-1 and SUMO-2/3 in LMP1-positive Lymphomas and Cells.
|
30659232 |
2019 |
|
Myopathy
|
0.010 |
Biomarker
|
group |
BEFREE |
Thus, our findings add this SUMO1 post-translational modification as a new concept to understand muscle disorders related to the defect in MuRF1 activity.
|
29868881 |
2019 |
|
Myeloproliferative disease
|
0.010 |
Biomarker
|
group |
BEFREE |
ZNF198, a zinc finger protein rearranged in myeloproliferative disease, localizes to the PML nuclear bodies and interacts with SUMO-1 and PML.
|
17027752 |
2006 |
|
Prostatic Neoplasms
|
0.010 |
AlteredExpression
|
group |
LHGDN |
Induction of the SUMO-specific protease 1 transcription by the androgen receptor in prostate cancer cells.
|
17932034 |
2007 |
|
Virus Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
To our knowledge, this is the first report showing that SUMO1 regulates lipid droplets in the context of viral infection.
|
26449956 |
2016 |
|
Congenital heart disease
|
0.010 |
Biomarker
|
group |
BEFREE |
We previously reported that knockout of SUMO-1 in mice led to congenital heart diseases (CHDs).
|
22155005 |
2012 |
|
Neoplasm Invasiveness
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Proteome analysis of hepatocellular carcinoma cell strains, MHCC97-H and MHCC97-L, with different metastasis potentials.
|
15048980 |
2004 |
|
Isolated cases
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Carcinogenesis
|
0.070 |
AlteredExpression
|
phenotype |
BEFREE |
An increased immunohistochemical expression of Snail1, Sumo1, TβRI, Hes1, and c-Jun was observed in aggressive prostate cancer tissues, consistent with their functional roles in tumorigenesis.
|
29228645 |
2017 |
|
Carcinogenesis
|
0.070 |
Biomarker
|
phenotype |
BEFREE |
Apart from their structural similarities the four proteins progesterone membrane component 1 (PGRMC1, also referred to as IZA, sigma-2 receptor, Dap1), PGRMC2, neudesin (NENF) and neuferricin (CYB5D2) display surprisingly divergent and multifunctional physiological properties related to cholesterol/steroid biosynthesis, drug metabolism and response, iron homeostasis, heme trafficking, energy metabolism, autophagy, apoptosis, cell cycle regulation, cell migration, neural functions, and tumorigenesis and cancer progression.
|
28396637 |
2017 |
|
Carcinogenesis
|
0.070 |
Biomarker
|
phenotype |
BEFREE |
Our results indicated that the SUMO1 acceptor site of NRF2 is the conserved lysine residue 110 (K110), and that NRF2 SUMOylation deficiency inhibited tumorigenesis in hepatocellular carcinoma (HCC).
|
31546024 |
2019 |
|
Carcinogenesis
|
0.070 |
Biomarker
|
phenotype |
BEFREE |
Our findings identify SUMO1 as a novel key regulator of EphB1-mediated tumorigenesis.
|
29550816 |
2018 |
|
Carcinogenesis
|
0.070 |
Biomarker
|
phenotype |
BEFREE |
SUMO1 modification of PTEN regulates tumorigenesis by controlling its association with the plasma membrane.
|
22713753 |
2012 |
|
Carcinogenesis
|
0.070 |
AlteredExpression
|
phenotype |
BEFREE |
The expression of SUMO-1 in OLP was similar to NM and IFH, suggesting that alterations of this protein occur at later stages of carcinogenesis, because important overexpression occurred in oral epithelial dysplasia and OSCC.
|
23350884 |
2013 |
|
Carcinogenesis
|
0.070 |
Biomarker
|
phenotype |
BEFREE |
The soft-agar colony formation, migration, vasculogenic mimicry (VM) and three-dimensional (3D) cell culture assays were performed to detect the phenotypes of tumor cells in vitro, and the xenograft tumor model in mice was conducted to verify that SUMO1 modification of KHSRP regulated tumorigenesis in vivo.
|
29020972 |
2017 |
|
Tumor Cell Invasion
|
0.050 |
AlteredExpression
|
phenotype |
BEFREE |
The increase in SUMO-1 activity prompted the SUMOlyation of target proteins which may be involved in proliferation and invasion.
|
27230680 |
2016 |
|
Tumor Cell Invasion
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
Our results provide evidence that SUMO1 promotes the proliferation and invasion of NSCLC cells by regulating NF-κB.
|
30393970 |
2019 |
|
Tumor Cell Invasion
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
SUMO-1 suppression by small interference RNA (siRNA) reduced migration and invasion as well as MMP-1 and MMP-3 expression in RA FLSs.
|
30562482 |
2019 |
|
Tumor Cell Invasion
|
0.050 |
AlteredExpression
|
phenotype |
BEFREE |
A marked expression of sentrin-1 mRNA could be seen in all RA synovial specimens, predominantly in SF of the lining layer and at sites of invasion of RA synovium into cartilage.
|
10728754 |
2000 |
|
Tumor Cell Invasion
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
Inhibiting SUMO1-mediated SUMOylation induces autophagy-mediated cancer cell death and reduces tumour cell invasion via RAC1.
|
31578236 |
2019 |
|
Tumor Progression
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Our data demonstrate how the miRNA biogenesis pathway is connected to tumorigenesis and cancer progression through the reversible SUMO1 modification of KHSRP.
|
29020972 |
2017 |
|
Tumor Progression
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Apart from their structural similarities the four proteins progesterone membrane component 1 (PGRMC1, also referred to as IZA, sigma-2 receptor, Dap1), PGRMC2, neudesin (NENF) and neuferricin (CYB5D2) display surprisingly divergent and multifunctional physiological properties related to cholesterol/steroid biosynthesis, drug metabolism and response, iron homeostasis, heme trafficking, energy metabolism, autophagy, apoptosis, cell cycle regulation, cell migration, neural functions, and tumorigenesis and cancer progression.
|
28396637 |
2017 |
|
Anoxia
|
0.010 |
Biomarker
|
phenotype |
LHGDN |
Furthermore, SUMO-1 overexpression stabilizes CREB in hypoxia and enhances CREB-dependent reporter gene activity.
|
12552083 |
2003 |
|
Neoplasm Metastasis
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
Patients who showed high dual expressions of SUMO-1 and p53 tended to experience metastasis more frequently.
|
23640307 |
2013 |